<DOC>
	<DOCNO>NCT01469520</DOCNO>
	<brief_summary>The purpose study determine bioavailability/bioequivalence two pediatric formulation ( tablet reconstitutable suspension ) lamivudine/zidovudine/ nevirapine comparison innovator product . Establishing bioequivalence newly develop age-appropriate fix dose combination lamivudine/zidovudine/ nevirapine oral dispersible tablet reconstitutable suspension child invaluable future product registration availability product child , thus fill void pediatric HIV/AIDS therapy .</brief_summary>
	<brief_title>Bioequivalence Study Pediatric Formulations Treat HIV Infection</brief_title>
	<detailed_description>Volunteer Selection Size : The International Conference Harmonization ( ICH ) guideline E11 clinical investigation medicinal product pediatric population suggest relative bioavailability comparison pediatric formulation , adult subject may use . Therefore , study perform minimum 24 healthy adult subject . However , 29 healthy adult enrol allow two possible drop-outs three subject may develop hypersensitivity nevirapine know hypersensitivity side effect , form rash . In anticipation reactions,10 % 26 subject add group . This make total 29 volunteer study . Advertisements announce study post Bowen University Teaching Hospital two month commencement study invite volunteer . Informed Consent Procedure : The volunteer screen use questionnaire ( see attach ) . The language communication English local language use community . Researchers explain volunteer individual basis , nature study , would expect right . Volunteers may choose drop study time without restriction . Volunteers inform screen procedure also include physical examination laboratory test . Following informed consent , use Consent Participate Form ( see attach ) counseling , volunteer may enrol study . A baseline laboratory test : pack cell volume , white blood cell count differentiation , platelet estimation , liver function ( aspartate aminotransferase [ SGOT ] , alanine aminotransferase [ SGPT ] ) , renal function ( serum creatinine ) , blood urea nitrogen ( BUN ) , pregnancy test ( female ) , HIV/AIDS , hepatitis B C test do two week prior dose . Volunteers may consume alcohol , tobacco , caffeine contain product , herbal drug study . Eligibility : The inclusion criterion follow : Adult male female find normal basis pre-trial physical examination , medical history result blood biochemistry hematology test ; subject competent willing sign inform consent form voluntarily give detailed information study ; willingness hospitalize 24-hour intensive sample period . Exclusion criterion : - Hypersensitivity study drug , alcoholism , anemia , evidence pregnancy - Abnormal laboratory test ; smoker ; - Any clinically significant disease finding screen medical history physical examination , opinion investigator , may interfere study ; - Treatment experimental prescribe drug within 30 day prior begin study Confidentiality : Volunteer 's name appear questionnaire link identification number . All document identification number instead name . The name use public document . All write material consent form store lock file researcher 's office . All material destroy shred five year completion research .</detailed_description>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>The eligibility criterion include adult 22 55 year ; Healthy determine basis pretrial physical examination , medical history , electrocardiogram result blood biochemistry hematology test ; Subject competent willing sign inform consent form voluntarily give detailed information study ; Willing hospitalize 24hour intensive sample period . The exclusion criterion hypersensitivity study drug ; Abnormal laboratory biochemistry value ; Smokers ; Any clinically significant disease finding screen , medical history physical examination , opinion investigator , may interfere study ; Treatment experimental drug within 30 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>Treatment</keyword>
</DOC>